GXH

No target or forward-work figure is disclosed in the supplied material, and no formal guidance is identified. The shape context is informative, however: HY22 represented only 39.3% of FY22 NPAT and 46.2% of FY22 revenue, so GXH historically earns materially more in the second half. Simple annualisation of HY23 revenue gives NZ$710.2m, about 6.0% above FY22's NZ$670.3m, but if the usual second-half weighting holds, full-year revenue and earnings would print meaningfully higher than a doubling of HY23. The release supports a stronger FY23 shape than FY22; it does not, on its own, establish a new run-rate because pharmacy momentum is the swing factor for 2H.

• What caused the Community Health margin to more than double, and is the HY23 level sustainable into 2H?
• Why did pharmacy segment profit fall despite revenue growth — cost inflation, mix, or specific regulatory/funding pressure?
• Why did the effective tax rate rise from 26.8% to 30.3%, and is 30%+ the right forward assumption?
• What is management's FY23 expectation, and is there any forward-work or contracted-revenue disclosure behind the Medical services step-up?
• How much of the net cash build reflects timing of payables (not disclosed) versus genuine operating accretion?

This briefing cannot assess valuation, management commentary tone, or any covenant, regulatory, or contract-renewal detail not contained in the supplied extraction.